caa a22 4500 469116935 CHVBK 20180323133127.0 cr unu---uuuuu 170328e19920901xx s 000 0 eng 10.1007/BF00170940 doi (NATIONALLICENCE)springer-10.1007/BF00170940 Suppression of high affinity IL-2 receptors on mitogen activated lymphocytes by glioma-derived suppressor factor [Elektronische Daten] [Lucinda Elliott, William Brooks, Thomas Roszman] Summary: Previously we have reported that human glial tumor cells secrete a factor(s) which suppresses the mitogen responsiveness of normal human peripheral blood lymphocytes (PBL) in a dose dependent manner. In this study we extend these observations and explore the possible mechanisms by which glioma-derived suppressor factor(s) (GSF) modulates lymphocyte reactivity. Preincubation of lymphocytes with GSF for 2 hrs induces suppression of lymphocyte mitogen responsiveness. GSF also inhibits production of interleukin-2 (IL-2) by mitogen activated human T-cells. Addition of delectinated or recombinant IL-2 to mitogen activated human T-cells in the presence of GSF does not restore the normal proliferative response of these cells. These findings suggest that GSF induces a defect in the expression of the receptor for IL-2 (IL-2R) on activated T-cells. Binding studies with radiolabeled IL-2 demonstrated that GSF suppresses and in some cases completely inhibits the expression of functional high affinity IL-2R on activated T-cells, thereby, preventing association of IL-2R with its receptor and the subsequent progression of the cell into the proliferative stage of the cell cycle. These cellular defects induced by GSF closely parallel the observed defects noted in T-cells obtained from patients with gliomas, indicating that the factors elicited from glial tumors may be responsible for the immunological deficits observed in patients with primary malignant intracranial tumors. Kluwer Academic Publishers, 1992 interleukin-2 (IL-2) nationallicence interleukin-2 receptor (IL-2R) nationallicence glioma-derived suppressor factor (GSF) nationallicence T-cells, mitogen responsiveness nationallicence Elliott Lucinda Department of Microbiology and Immunology, University of Kentucky Medical Center, 40536-0084, Lexington, KY, USA aut Brooks William Department of Microbiology and Immunology, University of Kentucky Medical Center, 40536-0084, Lexington, KY, USA aut Roszman Thomas Department of Microbiology and Immunology, University of Kentucky Medical Center, 40536-0084, Lexington, KY, USA aut Journal of Neuro-Oncology Kluwer Academic Publishers 14/1(1992-09-01), 1-7 0167-594X 14:1<1 1992 14 11060 https://doi.org/10.1007/BF00170940 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00170940 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Elliott Lucinda Department of Microbiology and Immunology, University of Kentucky Medical Center, 40536-0084, Lexington, KY, USA aut NATIONALLICENCE 700 1- Brooks William Department of Microbiology and Immunology, University of Kentucky Medical Center, 40536-0084, Lexington, KY, USA aut NATIONALLICENCE 700 1- Roszman Thomas Department of Microbiology and Immunology, University of Kentucky Medical Center, 40536-0084, Lexington, KY, USA aut NATIONALLICENCE 773 0- Journal of Neuro-Oncology Kluwer Academic Publishers 14/1(1992-09-01), 1-7 0167-594X 14:1<1 1992 14 11060 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer